Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) General Information
Description
Proprietary rights of CUTX-101, a Copper Histidinate product candidate for the treatment of Menkes disease.
Contact Information
Corporate Office
- New York, NY
- United States
Corporate Office
- New York, NY
- United States
Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) Patents
Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022240726-A1 | Copper histidinate compositions and uses thereof | Pending | 18-Mar-2021 | ||
| CA-3212536-A1 | Copper histidinate compositions and uses thereof | Pending | 18-Mar-2021 | ||
| EP-4308104-A1 | Copper histidinate compositions and uses thereof | Pending | 18-Mar-2021 | ||
| EP-4308104-A4 | Copper histidinate compositions and uses thereof | Pending | 18-Mar-2021 | ||
| WO-2022197948-A1 | Copper histidinate compositions and uses thereof | Inactive | 18-Mar-2021 | A61P25/00 |
Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) FAQs
-
Where is Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) headquartered?
Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) is headquartered in New York, NY.
-
What industry is Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) in?
Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York)’s primary industry is Buildings and Property.
-
Is Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) a private or public company?
Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) is a Private company.
-
What is the current valuation of Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York)?
The current valuation of Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) is .
-
What is Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York)’s current revenue?
The current revenue for Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) is .
-
Who are Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York)’s investors?
Cyprium Therapeutics has invested in Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York).
-
When was Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) acquired?
Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) was acquired on 24-Feb-2021.
-
Who acquired Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York)?
Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) was acquired by Sentynl Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process